GNCA - Genocea doses first patient in early-stage GEN-011 cancer study

Genocea Biosciences (GNCA) announces the dosing of the first patient in its TiTAN study, a Phase 1/2a clinical trial testing its GEN-011 therapy in certain patients with cancer.The company expects to report top-line results from the study on a subset of patients late in the fourth quarter of 2021 or the first quarter of 2022.GEN-011 represents a new category of autologous solid tumor cell therapy: neoantigen-targeted peripheral T cells (“NPTs”).

For further details see:

Genocea doses first patient in early-stage GEN-011 cancer study